bioAffinity Technologies expands at-the-market stock offering under Form S-3

bioAffinity Technologies filed a prospectus supplement dated November 2, 2026, tied to its Form S-3 registration statement, file number 333-275608. The supplement amends a prospectus supplement originally dated May 27, 2025, which was itself supplemented by a further prospectus supplement dated October 8, 2026, together referred to as the Prior Prospectus.¹

The underlying registration covers the offer and sale of common stock over time through WallachBeth Capital LLC acting as sales agent in at-the-market offerings, under a sales agreement dated May 22, 2025.¹ Since entering that agreement, bioAffinity has sold 114,672 shares for gross proceeds of about $1,300,000.¹

The new filing increases the amount available for sale under the agreement, adding up to $3,428,226 in common stock beyond what has already been sold.¹

As of the filing date, the market value of bioAffinity's common stock held by non-affiliates was about $27,684,678, based on 1,813,011 shares and a $15.27 closing price from September 4, 2026, the highest close in the prior 60 days.¹ Under Form S-3 rules, the company cannot sell more than one-third of that non-affiliate market value in any 12-month period while it remains under $75,000,000, and in the trailing twelve months through the filing date it had already sold $4,000,000 of stock under that same instruction.¹

bioAffinity's common stock trades on the Nasdaq Capital Market under the symbol BIAF, and closed at $2.91 per share on October 30, 2026.¹ The filing notes that investing in the stock involves a high degree of risk.¹